SCHEMBL6997121

SCHEMBL6997121

O=C1CNS(=O)(=O)c2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
KMT2A Q03164 2/20 0.52
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA4 P22748 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 1/20 0.52
BCHE P06276 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
GPR3 P46089 1/20 0.41
KEAP1 Q14145 1/20 0.41
ALPI P09923 6/20 0.40
ALPL P05186 3/20 0.40
HSD11B1 P28845 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL8644508 0.96 KDM4E (0.48) KDM4EKMT2ACA12CA1CA2
Ethylene SCHEMBL6989724 0.80 CA12 (0.36) KDM4EKMT2ACA12CA1CA2
Cyclopropane SCHEMBL6998820 0.80 KDM4E (0.36) KDM4EKMT2ACA12CA1CA2
SCHEMBL16831728 0.78 KDM4E (0.46) KDM4EKMT2ACA12CA1CA2
SCHEMBL18638475 0.78 KDM4E (0.46) KDM4EKMT2ACA12CA1CA2
SCHEMBL16852910 0.74 KDM4E (0.42) KDM4EKMT2ACA12CA1CA2
SCHEMBL18186992 0.74 KDM4E (0.42) KDM4EKMT2ACA12CA1CA2
SCHEMBL22451369 0.74 CA9 (0.42) KDM4ECA12CA1CA2CA4
SCHEMBL18065115 0.74 CYP2A6 (0.47) KDM4EKMT2ACA12CA1CA2
SCHEMBL61176 0.72 KEAP1 (0.44) KDM4EKMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190002454-A1 NRF2 Regulators GLAXOSMITHKLINE IP DEV LTD (GB) 2019-01-03 US disclosed
US-20190002454-A1 NRF2 Regulators GLAXOSMITHKLINE IP DEV LTD (GB) 2019-01-03 US disclosed
US-10144731-B2 Nrf2 regulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-12-04 US disclosed
US-20160318917-A1 NRF2 REGULATORS ASTEX THERAPEUTICS LIMITED (GB) 2016-11-03 US disclosed
US-20160318917-A1 NRF2 REGULATORS ASTEX THERAPEUTICS LIMITED (GB) 2016-11-03 US disclosed
US-20160318917-A1 NRF2 REGULATORS ASTEX THERAPEUTICS LIMITED (GB) 2016-11-03 US disclosed
CN-105829305-A NRF2 REGULATORS 葛兰素史密斯克莱知识产权发展有限公司 2016-08-03 CN disclosed
WO-2015092713-A1 NRF2 REGULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-06-25 WO disclosed
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
EP-0686632-B1 BENZOTHIAZINE DERIVATIVE DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-08-06 EP disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
US-5874429-A ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS SUNTORY LIMITED (JP) 1999-02-23 US disclosed
EP-0686632-A1 BENZOTHIAZINE DERIVATIVE SUNTORY LIMITED (JP) 1995-12-13 EP disclosed
US-5035739-A PLANT GROWTH REGULATORS IDEMITSU KOSAN COMPANY LIMITED (JP) 1991-07-30 US disclosed
US-4919705-A PLANT GROWTH REGULATORS IDEMITSU KOSAN COMPANY LIMITED (JP) 1990-04-24 US disclosed
EP-0305529-A1 TRIFLUOROMETHANESULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING SAME IDEMITSU KOSAN COMPANY LIMITED (JP) 1989-03-08 EP disclosed
US-4100347-A ANTIINFLAMMATORY AGENTS PFIZER INC. (US) 1978-07-11 US disclosed
US-3966716-A 2H-1,3,2-dioxaborino-[5,4-c]-1,2-benzo-thiazine 6,6-dioxides WARNER-LAMBERT COMPANY (US) 1976-06-29 US disclosed
US-3937828-A Substituted pyrano[3,2-c] [1,2]benzothiazine 6,6-dioxides WARNER-LAMBERT COMPANY (US) 1976-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002454-A1 NRF2 Regulators NFE2L2, KEAP1, NQO1 KDM4E 1805/4885KMT2A 1623/4885CA12 4870/4885
US-20160318917-A1 NRF2 REGULATORS NFE2L2, KEAP1, NQO1 KDM4E 1805/4885KMT2A 1623/4885CA12 4870/4885
US-10144731-B2 Nrf2 regulators NFE2L2, KEAP1, NQO1 KDM4E 1805/4885KMT2A 1623/4885CA12 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.